Metastatic Tumor Model Development

Metastatic disease continues to account for the majority of cancer mortality across global populations, underscoring the necessity for a detailed comprehension of the mechanisms governing metastatic spread in the design of efficacious interventions. Protheragen's metastatic tumor model development platforms deliver a robust resource for both academic investigation and therapeutic discovery. Our bespoke, fidelity-optimized models, augmented by specialized consultative expertise and cutting-edge technological suites, constitute an integrated framework for probing the metastatic cascade and for the preclinical evaluation of investigational agents.

Overview of Metastatic Tumor Models

Metastatic tumor models constitute essential platforms in oncological research, permitting controlled exploration of the multifaceted processes by which neoplastic cells migrate from a primary lesion to distant anatomical sites. Such models empower investigators to dissect every phase of the metastatic cascade—tumor cell invasion, entry into the vascular compartment, survival within the circulation, and the formation of metastatic colonies—under experimental conditions that approximate human disease.

Fig.1 Classic and new therapeutics for metastatic cancer. (Ganesh K., et al., 2021)

In contrast to models that interrogate neoplasm expansion at the primary site, metastatic systems are engineered to replicate the dislocation of cancer. They elucidate the dynamic interplay between tumor cells and the permissive microenvironment of remote organs, the mechanisms by which malignant cells endure the hemodynamic stress of the bloodstream, and the subsequent establishment of secondary loci in the lungs, liver, brain, and bone marrow. Collectively, these sequential phenomena underlie the lethality of the disease, as a substantial proportion of cancer fatalities is ascribed to the metastatic process rather than to the tumor of origin.

Metastatic Models for Cancer Therapeutics Development

The advancement of effective therapies for metastatic cancer hinges upon robust preclinical models that faithfully mirror the multifaceted nature of human disease. While conventional two-dimensional culture systems and subcutaneous xenografts provide valuable insight into primary tumor biology, they do not adequately reproduce the processes of metastasis. To overcome these deficiencies, cancer research laboratories have increasingly adopted metastatic tumor models that are now regarded as indispensable tools in drug discovery and therapeutic translation.

Such models facilitate the systematic evaluation of investigational agents throughout the continuum of metastatic spread. They permit interrogation of strategies designed not only to prevent the initial detachment of tumor cells but also to disrupt the establishment and growth of secondary lesions in distant sites. In particular, metastatic systems support the preclinical validation of agent-specific approaches that target the molecular machinery governing migration, invasion, and post-arrival survival of cancer cells in ectopic microenvironments.

Table 1. Examples of experimental and spontaneous in vivo models of metastasis. (Stribbling S. M., et al., 2024)

Our Services

At Protheragen, we provide an integrated package of metastatic tumor model development services customized to support the unique objectives of our partners in cancer research and therapeutic advancement. Our offerings span an extensive repertoire of metastatic models, encompassing:

Types of Metastatic Tumor Models

• Experimental Metastasis Models: Systemic (tail vein), intracardiac, or intracarotid injection routes to target lung, liver, brain, and bone metastases.
• Spontaneous Metastasis Models: Metastasis originating from orthotopic primaries; most faithful replication of human cancer progression.
• Lymphatic Metastasis Models: Designed to study lymph node invasion and immune evasion.

Optional Disease Models

Key Features of Our Services

• Tailored Model Development: We work with clients to develop models that meet their specific needs, whether for drug screening, mechanism of action studies, or biomarker discovery.
• Comprehensive Imaging Solutions: We offer advanced imaging techniques such as bioluminescence imaging (BLI), MRI, PET, and CT scans to monitor tumor growth, metastasis, and therapy responses in real time.
• Diverse Metastatic Models: Our portfolio includes orthotopic xenografts, PDXs, organoid-based models, and humanized mice, providing a comprehensive suite of models to study metastatic cancer from multiple angles.
• Preclinical Research: We offer robust preclinical testing services to evaluate the efficacy and safety of novel cancer therapies in metastatic models, helping to identify promising drug candidates.

Protheragen's metastatic tumor model development services are designed to provide our clients with a comprehensive and customizable approach to studying metastatic cancer. Our services span all stages of cancer drug development, from early-stage discovery to preclinical testing. We offer a range of models that allow for the in-depth study of cancer progression, metastasis, and treatment response, providing critical data to guide the development of novel therapies. If you are interested in our services, please feel free to contact us.

References

• Ganesh, Karuna, and Joan Massagué. "Targeting metastatic cancer." Nature medicine 27.1 (2021): 34-44.
• Stribbling, Stephen M., Callum Beach, and Anderson J. Ryan. "Orthotopic and metastatic tumour models in preclinical cancer research." Pharmacology & Therapeutics 257 (2024): 108631.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.